Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedOct 04, 2025
DataAggregated Company Financials
Companies547
  • 7D5.2%
  • 3M11.1%
  • 1Y-0.3%
  • YTD12.3%

The Biotech industry is up 5.2% in the last week, with AbbVie up 6.0%. Meanwhile, MoonLake Immunotherapeutics actually underperformed within the industry, shrinking 86% in the last week. The industry has been flat over the past 12 months despite the gain this week. As for the next few years, earnings are expected to grow by 25% per annum.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 04 Oct 2025US$1.1tUS$163.5b-US$18,206,071,363.5716.7x-61.8x6.9x
Mon, 01 Sep 2025US$1.1tUS$163.5b-US$18,373,688,758.5615.4x-57.4x6.5x
Wed, 30 Jul 2025US$978.3bUS$155.2b-US$22,170,866,971.1715.8x-44.1x6.3x
Fri, 27 Jun 2025US$928.2bUS$156.0b-US$23,838,153,787.8216.8x-38.9x6x
Sun, 25 May 2025US$907.6bUS$155.9b-US$24,118,382,442.0315.6x-37.6x5.8x
Tue, 22 Apr 2025US$757.2bUS$119.3b-US$36,503,635,360.2219.1x-20.7x6.3x
Thu, 20 Mar 2025US$833.1bUS$118.4b-US$37,426,956,446.7520.1x-22.3x7x
Sat, 15 Feb 2025US$843.4bUS$116.6b-US$36,838,403,221.2117.6x-22.9x7.2x
Mon, 13 Jan 2025US$947.7bUS$149.4b-US$26,263,014,335.7116.6x-36.1x6.3x
Wed, 11 Dec 2024US$1.0tUS$150.0b-US$26,535,944,620.1117.9x-39x6.9x
Fri, 08 Nov 2024US$1.1tUS$149.1b-US$31,021,469,881.2517x-35.4x7.4x
Sun, 06 Oct 2024US$889.8bUS$113.1b-US$35,952,253,973.7722x-24.8x7.9x
Tue, 03 Sep 2024US$909.4bUS$113.1b-US$35,704,251,292.6924x-25.5x8x
Thu, 01 Aug 2024US$1.2tUS$165.1b-US$29,392,630,542.9630.2x-41.8x7.4x
Sat, 29 Jun 2024US$1.1tUS$164.4b-US$28,157,592,218.3728.5x-40.7x7x
Mon, 27 May 2024US$1.1tUS$164.6b-US$26,653,350,594.7223.8x-42.2x6.8x
Wed, 24 Apr 2024US$1.1tUS$164.3b-US$23,439,543,461.9720.4x-46.7x6.7x
Fri, 22 Mar 2024US$1.2tUS$164.3b-US$23,898,885,613.2121.6x-48.8x7.1x
Sun, 18 Feb 2024US$1.2tUS$169.1b-US$20,519,191,458.5815.7x-56.9x6.9x
Tue, 16 Jan 2024US$1.4tUS$204.8b-US$22,498,525,782.0018.8x-63.9x7x
Thu, 14 Dec 2023US$1.3tUS$204.7b-US$22,099,611,280.0019.6x-59.9x6.5x
Sat, 11 Nov 2023US$1.2tUS$204.5b-US$22,053,784,561.0018.5x-54.1x5.8x
Mon, 09 Oct 2023US$1.3tUS$207.4b-US$13,060,168,797.0017.2x-96.4x6.1x
Wed, 06 Sep 2023US$1.3tUS$207.5b-US$12,513,012,217.0017.2x-102x6.2x
Fri, 04 Aug 2023US$1.1tUS$183.2b-US$17,641,388,597.0014.5x-64.3x6.2x
Sun, 02 Jul 2023US$1.1tUS$186.2b-US$16,042,400,813.0013.7x-70x6x
Tue, 30 May 2023US$1.1tUS$185.9b-US$16,045,777,796.0011.2x-69.9x6x
Thu, 27 Apr 2023US$1.2tUS$198.5b-US$3,096,107,692.0012.8x-375.3x5.9x
Sat, 25 Mar 2023US$1.1tUS$199.3b-US$3,645,756,952.0013.4x-310.8x5.7x
Mon, 20 Feb 2023US$1.2tUS$202.6b-US$64,851,937.0016.5x-17789.6x5.7x
Wed, 18 Jan 2023US$1.2tUS$203.6bUS$1.7b14.6x683.1x5.8x
Fri, 16 Dec 2022US$1.2tUS$203.3bUS$1.6b14.5x734.9x5.7x
Sun, 13 Nov 2022US$1.1tUS$202.2bUS$1.1b14.6x1045.5x5.5x
Tue, 11 Oct 2022US$1.0tUS$205.9bUS$5.4b14.9x192.3x5x
Price to Earnings Ratio

192.3x


Total Market Cap: US$1.0tTotal Earnings: US$5.4bTotal Revenue: US$205.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 31.7x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.5x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.4% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.16%
Healthcare6.62%
Biotech5.18%
Biotech5.18%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$233.916.0%
+US$23.5b		20.4%PE111x
AMGN AmgenUS$297.899.1%
+US$13.4b		-6.8%PE24.2x
VRTX Vertex PharmaceuticalsUS$403.304.6%
+US$4.5b		-11.4%PE28.4x
INSM InsmedUS$157.1614.7%
+US$4.3b		117.5%PS83.4x
REGN Regeneron PharmaceuticalsUS$600.006.4%
+US$3.7b		-40.8%PE14x

Latest News

BIIB
US$159.88
Biogen
7D
16.4%
1Y
-13.9%
ONC
US$343.87
BeOne Medicines
7D
5.5%
1Y
39.8%

Oncology Trials And Global Expansion Will Unlock Future Markets

Analysts have increased their fair value price target for BeOne Medicines by approximately $5 to $372.97. They cite robust Q2 sales growth, encouraging pipeline developments, and upward revisions to revenue forecasts as reasons for the adjustment.
INSM
US$157.16
Insmed
7D
14.7%
1Y
117.5%

Brensocatib's 2025 Launch Will Transform Bronchiectasis Care

Insmed's analyst price target has increased by over $6 to $164.41, as analysts cite stronger revenue growth projections and recent clinical and commercialization achievements as key catalysts for the upward revision. Analyst Commentary Recent analyst activity around Insmed highlights a dynamic mix of optimism and caution, reflecting both the company's clinical progress and commercial prospects.
AMGN
US$297.89
Amgen
7D
9.1%
1Y
-6.8%
ABBV
US$233.91
AbbVie
7D
6.0%
1Y
20.4%
HALO
US$68.98
Halozyme Therapeutics
7D
-6.5%
1Y
16.6%
REGN
US$600.00
Regeneron Pharmaceuticals
7D
6.4%
1Y
-40.8%
MLTX
US$8.43
MoonLake Immunotherapeutics
7D
-86.4%
1Y
-84.8%
MRUS
US$94.29
Merus
7D
36.9%
1Y
82.1%
VRTX
US$403.30
Vertex Pharmaceuticals
7D
4.6%
1Y
-11.4%
NBIX
US$137.03
Neurocrine Biosciences
7D
-3.5%
1Y
20.2%
MENS
US$48.00
Jyong Biotech
7D
-19.7%
1Y
n/a
LEGN
US$32.06
Legend Biotech
7D
-3.9%
1Y
-34.7%

Next Generation Cell Therapy Will Expand Global Patient Access

Analysts raised Legend Biotech's price target slightly to $77.46, citing growing conviction in Carvykti's commercial success and the company's strengthening leadership in cell therapy, which supports expectations for sustained growth. Analyst Commentary Carvykti has rapidly become the most successful CAR T-cell therapy on the market.
SLNO
US$59.21
Soleno Therapeutics
7D
-8.9%
1Y
19.3%
ADMA
US$14.66
ADMA Biologics
7D
-6.1%
1Y
-27.7%
AUPH
US$11.35
Aurinia Pharmaceuticals
7D
-13.6%
1Y
59.4%